[16] The therapeutic arm taking 500 mg green tea extract three times daily for 16 weeks showed increased GLP-1 levels that were not observed in the placebo group
Retatrutide, an innovative agent undergoing Phase III trials for obesity, T2DM, and non-alcoholic fatty liver disease, has demonstrated encouraging outcomes
The medication is administered via subcutaneous injection, typically on a weekly basis, though dosing frequency and amounts may be individualized based on patient response and tolerability
Retatrutide sIde effects like nausea, diarrhea, and constipation are more common at higher doses and tend to occur mainly during the dose-escalation period
Alcohol contributes excess calories and may worsen gastrointestinal side effects associated with GLP-1-based agents
While it is still not FDA-approved, it is being clinically tested and studied as a solution for obesity